Key clinical point: Use vs no use of sodium-glucose cotransporter-2 (SGLT2) inhibitors was associated with a lower risk for new-onset stroke (NOS) among patients with type 2 diabetes (T2D), with risk reductions being greater among those receiving concurrent statins, biguanides, thiazolidinediones, and glucagon-like peptide-1 receptor agonists (GLP-1 RA).
Major finding: The risk for NOS was significantly lower among SGLT2 inhibitor users vs nonusers (adjusted hazard ratio [aHR] 0.85; 95% CI 0.82-0.88), with similar results being reported in patients receiving statins (aHR 0.84; 95% CI 0.81-0.86), biguanides (aHR 0.77; 95% CI 0.75-0.79), thiazolidinediones (aHR 0.89; 95% CI 0.85-0.93), and GLP-1 RA (aHR 0.84; 95% CI 0.71-0.98).
Study details: The data come from a retrospective population-based cohort study including 232,101 patients with T2D using an SGLT2 inhibitor who were matched with 464,202 patients with T2D not using an SGLT2 inhibitor.
Disclosures: This study was supported by grants from Chung Shan Medical University Hospital. The authors declared no competing interests.
Source: Lin TK et al. Sodium-glucose co-transporter-2 inhibitors reduce the risk of new-onset stroke in patients with type 2 diabetes: A population-based cohort study. Front Cardiovasc Med. 2022;9:966708 (Aug 9). Doi: 10.3389/fcvm.2022.966708